GSK eyes prime FTSE 100 slot for standalone HIV drugs business

[riky]

GSK eyes prime FTSE 100 slot for standalone HIV drugs business

<p><a href="http://news.yahoo.com/glaxosmithkline-holds-dividend-eyes-ipo-hiv-unit-113317611--finance.html"><img src="http://l2.yimg.com/bt/api/res/1.2/2921VfuJkNSJsKLyLLxvbg--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2014-10-22T113349Z_2_LYNXNPEA9L0GF_RTROPTP_2_GSK-CHINA.JPG" width="130" height="86" alt="A no entry sign is pictured outside the GlaxoSmithKline building in Hounslow, west London" align="left" title="A no entry sign is pictured outside the GlaxoSmithKline building in Hounslow, west London" border="0" /></a>By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline , battered by weak U.S. drug sales and a bribery scandal in China, is looking to float its fast-growing HIV drugs business as part of a recovery plan that includes a fresh round of cost cutting. As a standalone company ViiV Healthcare would be among the top 40 companies in London's FTSE 100 index, outranking such household names as retailer Marks and Spencer , GSK Chief Executive Andrew Witty told reporters. Analysts at Jefferies said they valued the HIV and AIDS division at about 17 billion pounds ($27 billion). ...</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login